Latest Conference Articles

January 17th 2015, 12:36pm

Gastrointestinal Cancers Symposium (ASCO GI)

An analysis of patients with advanced hepatocellular carcinoma and elevated α-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.

January 17th 2015, 12:02pm

Gastrointestinal Cancers Symposium (ASCO GI)

Expanded analysis of the NAPOLI-1 trial's per-protocol population continues to support the benefit of adding the nanoliposomal encapsulation of irinotecan MM-398 to 5-fluorouracil plus leucovorin for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine.

January 17th 2015, 10:54am

Gastrointestinal Cancers Symposium (ASCO GI)

Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR), data from a retrospective study reported at the 2015 Gastrointestinal Cancers Symposium showed.

January 17th 2015, 10:29am

Gastrointestinal Cancers Symposium (ASCO GI)

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a combination treatment of PF-04136309 with FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma (PC).

January 16th 2015, 4:38pm

Gastrointestinal Cancers Symposium (ASCO GI)

Manish A. Shah, MD, talks about a recent phase II study of mFOLFOX paired with the MET inhibitor onartuzumab for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma (GEC).

January 16th 2015, 4:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Changing the administration schedule for gemcitabine plus nab-paclitaxel from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer.

January 16th 2015, 3:27pm

Gastrointestinal Cancers Symposium (ASCO GI)

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide.

January 16th 2015, 3:21pm

Gastrointestinal Cancers Symposium (ASCO GI)

The CLARINET study led to the approval of lanreotide (Somatuline Depot) for the treatment of patients with advanced unresectable, metastatic gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs.)

January 16th 2015, 9:27am

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with advanced, MET-amplified gastroesophageal cancer had a high likelihood of response to an investigational MET inhibitor, results from a preliminary, dose-escalation trial suggested.

January 15th 2015, 4:53pm

Gastrointestinal Cancers Symposium (ASCO GI)

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

January 15th 2015, 4:48pm

Gastrointestinal Cancers Symposium (ASCO GI)

Chiara Cremolini, MD, discusses findings from the phase III TRIBE trial that combined FOLFOXIRI with bevacizumab as a frontline treatment for patients with metastatic colorectal cancer.

January 15th 2015, 4:31pm

Gastrointestinal Cancers Symposium (ASCO GI)

Eric Van Cutsem, MD, PhD of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the use of trastuzumab for the treatment of advanced HER2-positive gastric cancer.

January 12th 2015, 4:22pm

Gastrointestinal Cancers Symposium (ASCO GI)

Intensifying the chemotherapy component of a standard first-line bevacizumab-containing regimen reduced the risk of death by about 20% and doubled the 5-year overall survival (OS) rate among patients with metastatic colorectal cancer (mCRC).

January 12th 2015, 3:57pm

Gastrointestinal Cancers Symposium (ASCO GI)

A 'watch and wait' surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery.

January 12th 2015, 3:31pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment.

January 12th 2015, 3:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.

December 17th 2014, 10:56am

San Antonio Breast Cancer Symposium

William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the BOLERO-1 Trial.

December 16th 2014, 2:49pm

San Antonio Breast Cancer Symposium

As few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

December 16th 2014, 11:34am

ASH Annual Meeting and Exposition

Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.

December 16th 2014, 9:56am

ASH Annual Meeting and Exposition

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.